Cardiology
BIOTRONIK, Charité and GHCF launch digital cardiology partnership
May 28, 2026Biotronik, Cardiology
BIOTRONIK, Charité – Universitätsmedizin Berlin and the German Heart Center Foundation (GHCF) have announced a partnership focused on advancing digital …
New medtech company Carvolix created as Affluent Medical acquires Caranx Medical and Artedrone
February 16, 2026Research and Development Cardiology, Carvolix
Carvolix (formerly Affluent Medical), a commercial and clinical-stage biotechnology company developing AI-powered mini-robots and biomimetic implants, has completed the acquisition …
Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation
February 12, 2026Research and Development Cardiology, Rhythm AI, atrial fibrillation
Rhythm AI, a UK-based company specialising in atrial fibrillation procedures, has announced that its STAR Apollo Mapping System has received …
HeartBeat.bio and biotx.ai partner to develop new drugs for heart failure
July 7, 2025Mergers and Acquisitions, Research and Development AI, Cardiology, HeartBeat.bio, biotx.ai, heart failure
HeartBeat.bio and biotx.ai have entered a partnership to accelerate heart failure drug discovery by combining AI-driven genetics with human cardiac …
STENTiT treats first patient with regenerative stent for limb preservation
June 27, 2025Research and Development Cardiology, Medical University of Graz, STENTiT, chronic limb-threatening ischemia, clinical trial, limb amputation, peripheral artery disease, regenerative stent, resorbable fibrillated scaffold
STENTiT has announced the successful first patient implantation of its resorbable fibrillated scaffold (RFS), a new regenerative stent, as part …
Lexeo Therapeutics, PXV Funds and venBio launch new entity to advance RNA therapies for cardiac diseases
June 27, 2025Mergers and Acquisitions, Research and Development Cardiology, Lexeo Therapeutics, PXV Funds, RNA-based therapies, cardiac genetic medicine, venBio Partners
Lexeo Therapeutics has announced a strategic partnership with life sciences investors Perceptive Xontogeny Venture Funds (PXV Funds) and venBio Partners …
Tiakis Biotech appoints Christoph Schmidt to supervisory board
May 22, 2025Research and Development Cardiology, Tiakis Biotech, cardiovascular diseases, pulmonary arterial hypertension
Tiakis Biotech has announced the appointment of Christoph Schmidt to its supervisory board. Based in Kiel, Germany, the clinical-stage biotech …
Landmark BioVentures launches spin-off biotech to tackle fibrotic, neoplastic and neovascularised conditions
May 20, 2025Research and Development Aix-Marseille University, Cardiology, Corporate, Landmark BioVentures, Massalia Therapeutics, Oncology, cardiovascular research, oncology
Landmark BioVentures and researchers at Aix-Marseille University in Marseille, France, have launched Massalia Therapeutics. Marking Landmark’s seventh company, the spin-off …
Novo Nordisk unveils new semaglutide data on obesity and heart disease at ECO 2025
May 12, 2025Research and Development Cardiology, Novo Nordisk, Obesity, Ozempic, cardiometabolic conditions, heart disease, obesity, semaglutide
Danish biopharma, Novo Nordisk, has announced that it will present new data on metabolic and cardiovascular health at the upcoming …
AAX Biotech announces collaboration for cardiovascular antibody therapy
May 8, 2025Research and Development AAX Biotech, Cardiology, antibody therapies, collaboration, research and development
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of antibody-based therapies targeting cardiovascular disease. …
Study finds new test could better predict risk of heart disease
April 28, 2025Research and Development Cardiology, Chalmers University of Technologyu, Harvard, cholesterol tests, cvd
A study by Harvard University, US, and Chalmers University of Technology, Sweden, has found that measuring a lipoprotein marker combination …
Rybelsus found to reduce major adverse cardiovascular events in Novo Nordisk trial
April 1, 2025Research and Development Cardiology, Novo Nordisk, cardiometabolic diseases, research and development
Novo Nordisk announced results from its SOUL cardiovascular outcomes trial. Rybelsus (oral semaglutide) significantly reduced the risk of major adverse …
AnaCardio raises $19m in funding round for heart failure candidate
January 10, 2025Research and Development AnaCardio, Cardiology, cardiology, funding, heart failure
Swedish biopharmaceutical company AnaCardio has announced the completion of a Series A extension financing round that has raised $19m for …
Santhera Pharmaceuticals announces LIONHEART study results for corticosteroid vamorolone
October 1, 2024Research and Development Cardiology, Duchenne Muscular Dystrophy, Immunology, Santhera Pharmaceuticals, clinical studies
Santhera Pharma has announced the results of its LIONHEART study, which evaluated vamorolone – a corticosteroid – and confirmed its …
New Real-World Data Published in Journal of Cardiac Failure on Effectiveness
August 6, 2024Research and Development Cardiac, Cardiology, Pfizer
Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated with tafamidis. Walton Oaks, 6th August …
